Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
| Language | Translation |
|---|---|
English
|
Malignant neoplasm: Malignant melanoma of lip |
French
|
Mélanome malin de la lèvre |
| Level | Code | Title | |
|---|---|---|---|
| 1 | II | Neoplasms | |
| 2 | C00-C97 | Malignant neoplasms | |
| 3 | C43-C44 | Melanoma and other malignant neoplasms of skin | |
| 4 | C43 | Malignant melanoma of skin | |
| 5 | C43.0 | Malignant neoplasm: Malignant melanoma of lip |
| Active Ingredient | Description | |
|---|---|---|
| Dactinomycin |
Dactinomycin is an antineoplastic antibiotic derived from Streptomyces parvullus. Stable complexes are formed with DNA through intercalation and DNA-dependent RNA synthesis is selectively inhibited. Protein and DNA synthesis are inhibited to a lesser extent. |
|
| Interferon, alfa-2a |
|
|
| Ipilimumab |
Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of reactive T-effector cells which mobilize to mount a direct T-cell immune attack against tumour cells. |
|
| Pembrolizumab |
Pembrolizumab is a humanised monoclonal antibody which binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. |
